Tumor necrosis factor-alpha: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett No edit summary |
imported>Robert Badgett No edit summary |
||
| Line 2: | Line 2: | ||
In [[medicine]], '''tumor necrosis factor-alpha''' is a "serum glycoprotein produced by activated macrophages and other mammalian mononuclear leukocytes. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as '''TNF-alpha''', it is only 30% homologous to tnf-beta (lymphotoxin), but they share [[tumor necrosis factor receptor|TNF receptors]].<ref>{{MeSH}}</ref> | In [[medicine]], '''tumor necrosis factor-alpha''' is a "serum glycoprotein produced by activated macrophages and other mammalian mononuclear leukocytes. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as '''TNF-alpha''', it is only 30% homologous to tnf-beta (lymphotoxin), but they share [[tumor necrosis factor receptor|TNF receptors]].<ref>{{MeSH}}</ref> | ||
TNFR-Fc fusion protein (etanercept - pronounced et a ner' set) blocks the activity of TNF-alpha.<ref>{{MedMaster|Etanercept}}</ref> | ==Tumor necrosis factor inhibitors== | ||
* TNFR-Fc fusion protein (etanercept - pronounced et a ner' set) blocks the activity of TNF-alpha.<ref>{{MedMaster|Etanercept}}</ref> | |||
* Infliximab is a chimeric monoclonal antibody that blocks the action of TNF-alpha by binding to it.<ref>{{MedMaster|Infliximab}}</ref> | |||
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 15:19, 1 September 2008
In medicine, tumor necrosis factor-alpha is a "serum glycoprotein produced by activated macrophages and other mammalian mononuclear leukocytes. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to tnf-beta (lymphotoxin), but they share TNF receptors.[1]
Tumor necrosis factor inhibitors
- TNFR-Fc fusion protein (etanercept - pronounced et a ner' set) blocks the activity of TNF-alpha.[2]
- Infliximab is a chimeric monoclonal antibody that blocks the action of TNF-alpha by binding to it.[3]
References
- ↑ Anonymous (2024), Tumor necrosis factor-alpha (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Template:MedMaster
- ↑ Template:MedMaster